Current Insights on Multimedia Radiology Reports
In a video interview at the recent Radiological Society of North America (RSNA) conference, Wayne Dell, M.D., discussed retrospective research that examined the use of hyperlinked multimedia radiology reports across modality and subspecialty five years after initial implementation of the technology at the University of Virginia.
Looking at a year’s worth of diagnostic radiology reports (382,508), researchers at the University of Virginia saw increasing adoption of hyperlinked multimedia reporting among multiple subspecialties five years after initial implementation of the reporting technology (Vue Reporting, Philips), according to findings presented at the Radiological Society of North America (RSNA) conference.
Abdominal radiologists used hyperlinks in 75 percent of computed tomography (CT) reporting and 59 percent of magnetic resonance imaging (MRI) reporting, according to the research. The study showed hyperlinks were utilized in 78 percent of radiology reporting for chest MRIs and 60 percent of CT chest reports. Pediatric radiologists employed hyperlinked reports for 56 percent of their CT reports and 51 percent of MRI reports.
In a video interview from the RSNA conference, study co-author Wayne Dell, M.D., said hyperlinked multimedia radiology reports not only provide enhanced clarity for patients, they contribute to increased efficiencies for referring clinicians and radiologists as well.
“The hyperlinks help navigate sometimes hundreds or even a thousand images on an MRI with a click of a button,” pointed out Dr. Dell, a second-year resident in diagnostic radiology at the University of Virginia. “That is just a lot of time saved both for the referring clinician …, who may not have very much experience at all with reading a MRI scan, and with the radiologist down the line. When they read the new study and compare it to an old report, they don’t have to spend several seconds sifting through to find the pertinent findings. They can just click.”
(Editor’s note: For related content, see “Reinventing Radiology Reports in the Age of Value-Based Care,” “Emerging Insights on Improving Radiology Workflows” and “Emerging Concepts and Perspectives in Radiology: Video Interviews from RSNA 2022.”)
For more insights from Dr. Dell, watch the video below.
SNMMI: Botox May Facilitate Relief from Dry Mouth Side Effect of PSMA-Targeted Radiopharmaceuticals
June 25th 2025For patients being treated with radiopharmaceutical agents for metastatic prostate cancer, the combination of botulinum toxin and an anti-nausea patch led to a 30 percent reduction in PSMA uptake in the salivary glands, according to preliminary research findings presented at the SNMMI conference.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.
RSNA 2020: Addressing Healthcare Disparities and Access to Care
December 4th 2020Rich Heller, M.D., with Radiology Partners, and Lucy Spalluto, M.D., with Vanderbilt University School of Medicine, discuss the highlights of their RSNA 2020 session on health disparities, focusing on the underlying factors and challenges radiologists face to providing greater access to care.
SNMMI: What a New Meta-Analysis Reveals About Radiotracers for PET/CT Detection of PCa
June 22nd 2025While (68Ga)Ga-PSMA-11 offers a pooled sensitivity rate of 92 percent for prostate cancer, (18F)-based radiotracers may offer enhanced lesion detection as well as improved imaging flexibility, according to a meta-analysis presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
SNMMI: Can Multimodal Monitoring Bolster Outcomes with Pluvicto in Treating mCRPC?
June 22nd 2025Multimodal treatment monitoring, including SPECT/CT exams 24 hours after treatment with Lu-177 PSMA-617, may have facilitated significantly shorter therapy durations and reduced side effects in patients with mCRPC, according to a two-year study presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
